Chugai, Fujifilm Of Japan Work With Academia For Cancer Antibodies
This article was originally published in PharmAsia News
Executive SummaryJapan drug makers Chugai Pharmaceutical and Fujifilm Holdings are working with academia to develop cancer antibodies
You may also be interested in...
A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies.
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.